Anthony B. Costales, M.D.
Picture
Positions
- Assistant Professor
-
Gynecologic Oncology
Dan L Duncan Comprehensive Cancer Center
²ÝÁñÉçÇøÈë¿Ú
Houston, Texas United States
Addresses
- Dan L Duncan Comprehensive Cancer Center (Clinic)
-
O’Quinn Medical Tower at Baylor St. Luke’s Medical Center’s McNair Campus
1919 Old Spanish Trail
Houston, TX 77054
United States
Phone: (832) 957-6500
Fax: (713) 610-4598
costales@bcm.edu
Education
- BS from Missouri State University
- 05/2008 - Springfield, Missouri United States
- Cell and Molecular Biology, Chemistry
- MD from The University of Texas at Houston McGovern Medical School
- 06/2012 - Houston, Texas United States
- Residency at The University of Texas at Houston McGovern Medical School- Memorial Hermann Hospital
- 06/2016 - Houston, Texas United States
- Obstetrics, Gynecology, and Reproductive Sciences
- Fellowship at Cleveland Clinic Foundation
- 06/2019 - Cleveland, Ohio United States
- Gynecologic Oncology
Certifications
- MD
- #S2006 (06/02/2019 - 05/01/2020)
- Texas Medical License
- Board eligible in Obstetrics & Gynecology
- American Board of Obstetrics & Gynecology
- Board eligible in Gynecologic Oncology
- American Board of Obstetrics and Gynecology
Honors & Awards
- 2020 Texas Super Doctors Rising Stars
- https://www.superdoctors.com/texas/
- Super Doctors (07/2020)
- 2021 Texas Super Doctors Rising Stars
Professional Interests
- Hyperthermic intraperitoneal chemotherapy (HIPEC)
- Minimally invasive surgery for gynecologic cancers
- Sentinel lymph node mapping for gynecologic cancers
- Treatment of ovarian cancer
- Treatment of cervical cancer and pre-invasive disease
- Treatment of uterine cancer and pre-invasive disease
- Treatment of vulvar cancer and pre-invasive disease
- Treatment of vaginal cancer and pre-invasive disease
- Treatment of uterine sarcomas
- Management of hereditary breast and ovarian cancer syndromes
- Fertility-sparing treatment of gynecologic cancers
- Complex gynecologic surgery
Professional Statement
Anthony B. Costales, M.D. is an Assistant Professor in the Department of Gynecologic Oncology. He graduated residency in Obstetrics and Gynecology from the McGovern Medical School at UTHealth. He then completed his fellowship in Gynecologic Oncology at the Cleveland Clinic Foundation.Dr. Costales provides both medical and surgical care to women with gynecologic cancers. He performs minimally invasive surgery, both robotic and laparoscopic surgery, for appropriate patients with uterine and early-stage ovarian cancers. Dr. Costales also has a special interest in the use of hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancers.
Along with providing excellent care to his patients, Dr. Costales’ primary research interests include surgical clinical trials to optimize outcomes in gynecologic cancer patients. Specifically, he is pursuing study in the advancement of the role of minimally invasive surgery in gynecologic oncology, as well as the use of HIPEC in advanced and recurrent ovarian cancers. Dr. Costales believes in the early adoption of technology to improve outcomes in his patients. He has authored and co-authored numerous articles in peer-reviewed journals on these and other subjects.
With his free time, Dr. Costales enjoys playing all sports, in particular soccer, working out at his CrossFit gym, traveling around the world with his family, and going to the dog park with his American Bulldog-Pitbull mix named Jorge.
Websites
Dr. Anthony B. Costales on FOX26 discussing the importance of cervical cancer screening
Anthony B. Costales, MD, of the ²ÝÁñÉçÇøÈë¿Ú, discusses results from the MIID-SOC trial, which explored the question of whether laparoscopic surgery for removal of ovarian, fallopian tube, or primary peritoneal cancer following neoadjuvant chemotherapy is feasible, safe, and provides similar outcomes as open surgery.
Professional Development
- Robotic Training Network Curriculum
- Course (Participant, 2019)
- Sponsor: Institute of Surgical Excellence
- Robotic training certification
Selected Publications
- Costales AB, Radeva M, Ricci S. "Characterizing the efficacy of adjuvant therapy versus observation in women with early stage (uterine confined) leiomyosarcoma: A National Cancer Database study." JGO. 2019 Sep;(Accepted- in Press)
- Costales AB, Michener CM, Escobar-Rodriguez PF "." Curr Treat Options Oncol. 2018 Nov 19;12(75):s11864-018-0591-4. Pubmed PMID:
- Costales AB, Patil D, Mulya A, Kirwan JP, Michener CM "." J Surg Research. 2018 Jun;226:166-172. Pubmed PMID:
- Connor EV, Moulton LJ, Costales AB, Vargas R, Michener CM, AlHilli MM. "." Int J Gynecol Cancer. 2018 Mar 27;28(5):983-988. Pubmed PMID:
- Pontremoli Salcedo M, Costales AB, Munsell MF, Ramalingam P, Dos Reis R, Milbourne AM, El Beitune P, Schmeler KM "." European Oncology & Haematology.. 2017;13(1):24-27.
- Smith JA, Costales AB, Jaffari M, Urbauer DL, et al. "." J Oncol Pharm Pract. 2016 Aug;22(4):599-604. Pubmed PMID:
- Costales AB, Agarwal AK, Refuerzo JS, Chauhan SP, et al. "." AJP Rep. 2015 Apr;5(1):e25-29.. Pubmed PMID:
- Costales AB, Schmeler KM, Broaddus R, Frumovitz M, et al. "." 2014 Dec;135(3):451-454. Pubmed PMID:
- Costales AB, Milbourne AM, Rhodes HE, Schmeler KM, et al. "." Gynecol Oncol.. 2013 Jun;129(3):513-516. Pubmed PMID:
- Costales AB, Eifel PJ, Deavers MT, Frumovitz M, Schmeler KM. "." Gynecol Oncol Case Reports. 2012 May 9;2(3):97-99. Pubmed PMID:
- vii. Costales AB, Chambers L, Chichura A, Rose PG, Mahdi H, Michener CM, Yao M, Debernardo R. "." J Gynecol Obstet Hum Reprod. 2020 Jun; Pubmed PMID:
- vi. Chambers LM, Costales AB, Crean-Tate K, Kuznicki M, Morton M, Horowitz M, Jagielo T, Rose PG, Michener C, Vargas R, Debernardo R "." Gynecol Oncol. 2020 Sep; Pubmed PMID:
- v. Morton M, Chambers LM, Costales AB, Chichura A, Gruner M, Rose PG, Yao Yao M, Debernardo R, Michener CM "." Gynecol Oncol. 2021 Jan; Pubmed PMID:
- iv. Chichura A, Chambers LM, Costales AB, Yao M, Gruner M, Morton M, Rose PG, Vargas R, Michener CM, Debernardo R "." Gynecol Oncol. 2021 Jan; Pubmed PMID:
- iii. Chambers LM, Horowitz M, Costales AB, Yao M, Gruner M, Morton M, Chichura A, Rose P, Michener C, Debernardo R "." Gynecol Oncol. 2021 Feb; Pubmed PMID:
Projects
- Minimally invasive interval debulking surgery in ovarian cancer (MIID-SOC): A prospective pilot study
- Cleveland Clinic Foundation (01/2018 - present)
- Taussig Cancer Center
- https://consultqd.clevelandclinic.org/investigating-the-role-of-minimally-invasive-surgery-for-interval-debulking-in-advanced-ovarian-cancer/ https://clinicaltrials.gov/ct2/show/NCT03378128 https://www.gynecologiconcology-online.net/article/S0090-8258(19)30865-0/abstract
- Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer (MAN-U Trial)
- ²ÝÁñÉçÇøÈë¿Ú (04/2021 - present)
- Dan L Duncan Comprehensive Cancer Center
- This is a prospective, multi-center, randomized non-inferiority phase III study to evaluate if patients undergoing a minimally invasive surgery for early stage uterine cancer have cancer cells in the fluid that is obtained at the time of their surgery when a uterine manipulator is placed versus patients who do not have a uterine manipulator placed. https://clinicaltrials.gov/ct2/show/NCT04586959
Memberships
- Society of Gynecologic Oncology
- Full Member (07/2014)
- American College of Obstetrics and Gynecology
- Member (07/2011)
Languages
Spanish
to edit your profile
